Belvedere Trading LLC CURE — DIREXION SHS ETF TR

Ownership history in Belvedere Trading LLC  ·  9 quarters on record

AI Ownership Summary

Belvedere Trading LLC reported DIREXION SHS ETF TR (CURE) in 9 quarterly 13F filings from 2023 Q4 through 2026 Q1. The latest visible filing shows CURE at 0.00% of the fund.

This page tracks quarterly shares, estimated market value, portfolio weight, filing dates, and disclosure-aligned stock prices directly from SEC EDGAR 13F filings. Older history is available after unlock; the visible window still shows the most recent pattern.

What this CURE ownership page tells you

This page is designed to answer the real investor question behind a 13F filing: how meaningful was Belvedere Trading LLC's position in DIREXION SHS ETF TR, and how did that conviction change over time? You can read the holding window, peak weight, latest reported size, disclosure timing, and quarter-by-quarter changes without piecing the story together from raw SEC rows.

Freshest filing
Latest Reported Filing
2026 Q1

CURE was reported at 0.00% of portfolio in the most recent visible filing.

High-water mark
Peak Conviction
0.0% in 2026 Q1

Peak weight helps separate a token disclosure from a real conviction holding the fund genuinely cared about.

Time in book
Holding Window
2023 Q4 to 2026 Q1

Longer holding windows often tell a very different story from short-lived tactical trades or one-quarter experiments.

Decision context
Why It Matters
Position size beats headlines

Knowing that a fund owned a stock is useful. Knowing whether it was a 0.20% placeholder or a true high-conviction position is where the signal actually starts.

CURE stock page Belvedere Trading LLC fund profile Belvedere Trading LLC full holdings
How Belvedere Trading LLC held CURE — position size vs. price
% of Fund (quarterly)    CURE price (quarter-end, indexed to 100)    SPY (indexed to 100)    QQQ (indexed to 100)
📋 Quarterly Holdings History 6 quarters  ▾
Quarter Action Sold % After 3M Timing Shares Change Chg % % of Fund Mkt Value Filed Price (Filed)
2026 Q1 ADDED — — — 10,900 +7,199 +194.5% 0.00% $998K 2026-05-12 $88.48
2025 Q1 ADDED — — — 3,701 +1,501 +68.2% 0.00% $395K 2025-05-09 $75.52
2024 Q1 ADDED — — — 2,200 +1,322 +150.6% 0.00% $276K 2024-05-09 $109.74
2024 Q1 REDUCED 51.2% -8.2% ✅ 878 -922 -51.2% 0.00% $110K 2024-05-09 $109.74
2023 Q4 ADDED — — — 1,800 +1,100 +157.1% 0.00% $183K 2024-02-13 $112.01
2023 Q4 REDUCED 41.7% +20.5% ❌ 700 -500 -41.7% 0.00% $71K 2024-02-13 $112.01
3 older quarters hidden  —  Sign in free or upgrade to Premium to see full history

🏢 Other funds also holding CURE

As of 2026 Q1 — sorted by position size

GTS SECURITIES LLC 0.04% Traynor Capital Management, Inc. 3Y 7Y 0.03% Onyx Bridge Wealth Group LLC 3Y 0.02% SBI Securities Co., Ltd. 0.02% Pinnacle Wealth Planning Services, Inc. 3Y 7Y 0.0% Summit Financial, LLC 3Y 7Y 0.0% Tower Research Capital LLC (TRC) 3Y 7Y 0.0% CITADEL ADVISORS LLC 3Y 7Y 0.0% SUSQUEHANNA INTERNATIONAL GROUP, LLP 3Y 7Y 0.0% OSAIC HOLDINGS, INC. 3Y 0.0%

FAQ About Belvedere Trading LLC and CURE

These are the practical questions this page is built to answer before you even open the full history table.

How long has Belvedere Trading LLC reported owning CURE?

Belvedere Trading LLC reported CURE across 6 quarterly 13F filings, from 2023 Q4 through 2026 Q1.

What was the largest reported CURE position in Belvedere Trading LLC's portfolio?

The largest reported portfolio weight for CURE was 0.00% in 2026 Q1.

What is the latest reported CURE position on this page?

The most recent filing on this page is 2026 Q1, when Belvedere Trading LLC reported 10,900 shares, equal to 0.00% of portfolio, with an estimated market value of $998K.

What does the chart on this CURE ownership page compare?

The chart compares Belvedere Trading LLC's quarterly CURE portfolio weight with the stock's indexed share price, so you can see whether the fund was building, trimming, or holding the position as price moved.

How well did Belvedere Trading LLC time their CURE position?

Based on 13F filing dates vs. subsequent CURE price moves, Belvedere Trading LLC correctly timed 5 out of 8 reported position changes (62%).

← Back to Belvedere Trading LLC Holdings